After more than 5 decades of claiming that psychosis conditions like schizophrenia are caused by excessive dopaminergic activity and depression is a deficiency of serotonin, big pharma is doing 180 degrees reversal. A new drug was just approved for treating bipolar disorder and schizophrenia in adults, and its effects are basically a combination of cyproheptadine and bromocriptine - a combination we have discussed on the forum before. Keep in mind that current medical dogma states that the psychosis of conditions like schizophrenia is caused specifically by agonism of the D2 "receptor" and typical first-line therapy drugs for the condition are potent D2 antagonists, sometimes in combination with an SSRI.
This newly approved drug is an agonist of the D2 and 5-HT1 "receptors" (like bromocriptine) and antagonist of the 5-HT2 and H1 "receptors" (like cyproheptadine). Sometimes I wonder how can FDA approve two drugs with clearly opposite mechanisms of action without questioning the theory behind one or the other...
Cariprazine - Wikipedia, the free encyclopedia
New Antipsychotic Agent Available for Bipolar Mania, Schizophrenia
"...Vraylar is an atypical antipsychotic that exerts its effect through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. It acts as an antagonist at 5-HT2B and 5-HT2A receptors with high and moderate binding affinity as well as it binds to the histamine H1 receptors. Cariprazine shows lower binding affinity to the serotonin 5-HT2C and alpha1A- adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors."
This newly approved drug is an agonist of the D2 and 5-HT1 "receptors" (like bromocriptine) and antagonist of the 5-HT2 and H1 "receptors" (like cyproheptadine). Sometimes I wonder how can FDA approve two drugs with clearly opposite mechanisms of action without questioning the theory behind one or the other...
Cariprazine - Wikipedia, the free encyclopedia
New Antipsychotic Agent Available for Bipolar Mania, Schizophrenia
"...Vraylar is an atypical antipsychotic that exerts its effect through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. It acts as an antagonist at 5-HT2B and 5-HT2A receptors with high and moderate binding affinity as well as it binds to the histamine H1 receptors. Cariprazine shows lower binding affinity to the serotonin 5-HT2C and alpha1A- adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors."
Last edited: